Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) LT-Debt-to-Total-Asset : 0.03 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Laboratorio Farmaceutico Erfo SpA LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Laboratorio Farmaceutico Erfo SpA's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.03.

Laboratorio Farmaceutico Erfo SpA's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.03). It may suggest that Laboratorio Farmaceutico Erfo SpA is progressively becoming more dependent on debt to grow their business.

Laboratorio Farmaceutico Erfo SpA LT-Debt-to-Total-Asset Historical Data

The historical data trend for Laboratorio Farmaceutico Erfo SpA's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorio Farmaceutico Erfo SpA LT-Debt-to-Total-Asset Chart

Laboratorio Farmaceutico Erfo SpA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.03

Laboratorio Farmaceutico Erfo SpA Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					-	0.04	-	0.02	0.03

Laboratorio Farmaceutico Erfo SpA LT-Debt-to-Total-Asset Calculation

Laboratorio Farmaceutico Erfo SpA's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.242	/	9.377
	=	0.03

Laboratorio Farmaceutico Erfo SpA's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.242	/	9.377
	=	0.03

Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Laboratorio Farmaceutico Erfo SpA LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Laboratorio Farmaceutico Erfo SpA's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorio Farmaceutico Erfo SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Laboratorio Farmaceutico Erfo SpA (MIL:ERFO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Viale Geki Russo Lo. Pontegallo, Villafranca Tirrena, Messina, ITA, 98049

Website

https://www.erfo.it

Laboratorio Farmaceutico Erfo SpA operates in the nutraceutical sector. The company specializes in formulating and producing food supplements and natural medicines in different forms such as liquids, powders, granules, tablets, and soft gels. Geographically, the company generates a majority of its revenue from Italy followed by Spain, France, Belgium, and other countries.

Laboratorio Farmaceutico Erfo SpA Headlines

No Headlines